科瑞斯塔生物科技

最新新闻

• 评级变动
  Citi Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $386
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $361
  \u5e02\u573a\u8d44\u8baf · 2026/6/16
• 评级变动
  BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $364
  \u5e02\u573a\u8d44\u8baf · 2026/6/1
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Krystal Biotech (KRYS), AbbVie (ABBV) and Tempus AI, Inc. Class A (TEM)
  TipRanks · 2026/6/1
• 评级变动
  BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Cuts Target Price to $392
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $400
  \u5e02\u573a\u8d44\u8baf · 2026/9/21
• 评级变动
  BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $396
  \u5e02\u573a\u8d44\u8baf · 2026/7/14
• Jefferies Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $474
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 评级变动
  RBC Capital Initiates Krystal Biotech(KRYS.US) With Buy Rating, Announces Target Price $400
  \u5e02\u573a\u8d44\u8baf · 2026/8/15
• Krystal Biotech(KRYS.US) Director Sells US$8.23 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/8/15
• 评级变动
  BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/5/14
• 评级变动
  H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $361
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Announces Target Price $364
  \u5e02\u573a\u8d44\u8baf · 2026/5/22
• Goldman Sachs Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $441
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  TD Cowen Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $403
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  William Blair Maintains Krystal Biotech(KRYS.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  TD Cowen Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $403
  \u5e02\u573a\u8d44\u8baf · 2026/6/18
• 评级变动
  Wolfe Research Maintains Krystal Biotech(KRYS.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• Krystal Biotech(KRYS.US) 10% Shareholder Sells US$8.98 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/9/5
• 评级变动
  H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $310
  \u5e02\u573a\u8d44\u8baf · 2026/6/1

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。